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WOMEN IN CLINICAL TRIALS-WHERE ARE THEY?
BY JILLIAN HEMSTOCK
More women than men die each year of heart disease, even
though women are believed to live longer than men.1 This number
is at least 500,000 women every year, and even more astonishing is
that after suffering from a heart attack approximately 44% of
women will die within a year whereas for men, this percentage is
only at 27%.2 Heart disease remains to be the number one killer of
women, yet it is one of the most preventable diseases. In the past
three years, four out of ten prescription drugs withdrawn from the
market had induced potential fatal cardiac arrhythmias in women
more often than in men.3 The medical reason for this is that the
interval between the heart and muscle contractions is naturally
longer in women, and also male sex hormones may moderate the
heart muscle's sensitivity to the drug.4
New concepts for the prevention of heart disease and other
illnesses stem from clinical trials and the results that they produce.
Unfortunately there is a strong concern that women have been
highly underrepresented in clinical trials, especially those
performed on heart disease. A possible reason for this discrepancy
is the concern about the potential for harm on women of
childbearing age. Women's reproductive capabilities and their
potential fetuses have long been viewed as requiring protection
from the possible harms of medical research.5 From the early
1960's to the late 1970's women were greatly excluded from
medical research trials for these very reasons. 6 This came as aresult of infant abnormalities caused by the drugs that women were
1 Women and Cardiovascular Disease, available at http://www.americanheart.
org (last visited Mar. 30, 2004).
2 id.
3 Women's Health: Women Sufficiently Represented in New Drug Testing, but
FDA Oversight Needs Improvement, U.S. GAO-01-754 (2001).4 1d.
5 Keitt, Sarah K., Sex & Gender: The Politics, Policy, and Practice of Medical
Research, 3 YALE J. HEALTH POL'Y, L. & ETHics 253, 255 (2003).
6 id.
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taking either before or during their pregnancies. An example of
this was the drug Thalidomide which was prescribed to prevent
miscarriages and as a result caused birth defects. 7 In response to
the problems that came with taking this drug, the Kefauver-Harris
Amendment was passed in 1962 to protect children, pregnant
women, and fetuses. 8 Just a few years later, another prescription
drug given to prevent miscarriages, called Diethylstilbestrol (DES)
triggered a similar controversy. which was also given to women
to protect against miscarriages, and instead produced daughters
with reProductive abnormalities and an increased risk of vaginal
cancer.
The Food and Drug Administration (FDA) of the United
States had to step in to protect both women and their unborn
children. In 1977 The FDA issued guidelines that set forth a
policy stating that women of childbearing potential should be
excluded from the earliest studies of a new drug, meaning Phase 1
and Phase 2.11 The only exception was that women could be used
in early testing if the drug was intended for life-saving or life-
prolonging treatment. 12 During Phase 1 a drug is introduced in
humans for the first time to study its basic tolerance in the human
body, along with how it is metabolized.' 3 The next phase is Phase
2, which is when the initial controlled trials are performed to
determine a drug's effectiveness. 14 Both phases provide important
information on a drug's toxicity and safe dosing levels that is then
used in later stages of clinical development. Prohibiting women
from participating in these early phases may actually reduce the
number of women participating in the later stages of clinical trials.
7 U.S. GAO, supra note 3, at 9.
8 Keitt, supra note 5, at 253, citing, Drug (Kefauver-Harris) Amendments of
1962, Pub. L. No. 87-781; 76 Stat. 780 (codified as amended in scattered
sections of 21 U.S.C.).
9 U.S. GAO, supra note 3, at 9.
10 Id.
1 Guideline for the Study and Evaluation of Gender Differences in the Clinical
Evaluation of Drugs, 58 Fed. Reg. 39406, 39407 (proposed July 22, 1993)
[hereinafter Guideline].
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The reason for this is that safe dosing levels would not be known
and therefore could not be provided.
This represented a huge problem for medical research and
clinical trials performed on women. Men and women are
biologically different and therefore have very different genetic
make-ups. As a result men and women respond differently to the
same drugs because their bodies metabolize the drugs at different
rates. 15 This is similar to the way men and women metabolize
alcohol. Women, being naturally smaller in body size and muscle
mass than men, metabolize alcohol at different rates producing
different responses to the alcohol at different times. Other major
differences are the effect of a women's menstrual cycle on drug
interaction, the possibility that the woman is taking oral
contraceptives or other hormones which also may induce different
drug reactions.
Unfortunately the guidelines established by the FDA in
1977 gave the phrase "women of childbearing potential" a strict
definition, referring basically to all pre-menopausal women
capable of having children including women on oral
contraceptives, single women, celibate women, and even women
whose partners had been sterilized. 16 As a result all women before
the age of approximately 45 would be excluded from clinical trials.
This suppressed the possibility for new developments in women's
health care needs, especially in researching diseases that effect
only women or affect women differently than men.
In 1988 this policy was finally revised and a new guideline
was issued that concerned the format and content of a New Drug
Application's (NDA) clinical and statistical sections. They were
now to include possible blood concentration data for each patient,
adverse reactions, effectiveness, possibility of interactions with
oral contraceptives or any other medication, and dose response.17
This guidance issued by the FDA, however, did not have the force
of law and drug companies were only recommended to follow such
guidelines. With the passing of the Food and Drug Modernization
15 Guideline, supra note 10, at 39406.
16 Id. at 39408.
17 id.
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Act (FDAMA) in 1997 the FDA began to examine, more closely,
the issue of the inclusion of women in clinical trials. 18 Section 115
of FDAMA required that the Secretary "in consultation with the
Director of the National Institutes of Health and the representatives
of the drug manufacturing industry, review and develop guidance,
as appropriate, on the inclusion of women and minorities in
clinical trials."
' 19
In 1998 the FDA issued a regulation which required safety
and efficacy data already collected to be presented separately for
men and women in NDA summary documents. This regulation
had more power than a guidance. However, the problem here was
that the regulation was much less specific than the guidance and
also it did not include the specific number of women that should be
used in trials. 21 Drug companies were then left to determine how
many women to include, which could range anywhere from one to
1,000. The problem may have been that the FDA did not have the
tools to manage exactly how many women are to be used in a
clinical trial.
Later in 2000 the FDA issued yet another regulation. This
regulation allowed the FDA to halt research programs involving
drugs for life threatening conditions, but only if otherwise eligible
men or women were excluded from participating because of their
22reproductive potential. However, this regulation also did not
include the specific number of men or women that should be used
in clinical trials. To this day the FDA has not utilized this
authority.
23
While the FDA was taking slow strides toward bringing
more women into clinical trials for medical research, the National
18 Evelyn B., et al, Women's Participation in Clinical Trials and Gender Related
Labeling: A Review of New Molecular Entities Approved 1995-1999, Office of
Special Health Issues, Office of International and Constituent Relations, Office




20 U.S. GAO, supra note 3, at 4.
21 Id. at 9.
22 1d. at 3.
23 id.
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Institute of Health (NIH) was vastly expanding this policy area.
While the FDA policy stated that men and women should be
included in clinical trials, the NIH required that both be included
and that an analysis of gender differences be performed.24 The
NIH began this focus in 1986 when an advisory committee urged
grant applicants to consider including women in all clinical
research. Later in 1990 the Congressional Caucus for Women's
Issues worked with representative Henry Waxman in requesting a
General Accounting Office (GAO) report, which later became
known as the "smoking gun" for the neglect of women's health
26research. 6 The GAO report was based on the progress of
women's health research, which was not developing very quickly.
Following the hearing that was held as a result of the GAO report,
articles were rapidly published with titles such as "In Research,
Women Don't Matter" (Berney 1990), and "Wanted: Single, White
Male for Medical Research" (Dresser 1992).27
A greater effort, however, was made in 1991 when the NIH
established the Women's Health Initiative (WHI) which was a
multimillion dollar effort to study approximately 150,000 women
at over forty clinical centers all over the United States. The
1990's finally did see an improvement in the inclusion of women
in clinical trials. The WHI began to concentrate on the prevention
of diseases such as cardiovascular disease, osteoporosis, and
cancer, all diseases that greatly affect women, especially post-
menopausal women. The multimillion dollar endeavor included a
randomized clinical trial focused on approaches to preventing the
diseases, an observational study to identify predictors of the
diseases, and a study of community approaches to develop
24 Baird, Karen L, Motivation, Mobilization, and Monitoring: The Role of
Groups in Health Policy: The New NIH and FDA Medical Research Policies:
Targeting Gender, Promoting Justice, 24 J. HEALTH POL. POL'Y, & L. 531 at
549 (June, 1999).
25 Id. at 535.
26 Id.
27 Id. at 536.
28 Id. at 537.
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healthful behaviors. 29 The goal of this project was to reduce not
only heart disease, but also breast and colorectal cancers, dementia,
and bone fractures in postmenopausal women, by using strategies
for prevention along with understanding the risk factors of each
disease. 30 This inclusion of prevention of disease greatly pushed
women's medical research forward.
Another important study was performed on postmenopausal
women and was focused on Alzheimer's disease and women
taking combination hormone therapy. These women were found to
have a higher rate of dementia and therefore it was found that
women taking the estrogen-progestin combination therapy were
not protected against developing dementia. 31  The National
Institute on Aging was then able to successfully recommend that
combination hormone therapy not be prescribed for older
postmenopausal women. It was becoming clear that the inclusion
of women in clinical trials was improving the area of women's
health research by pushing it forward with confidence.
The Women's Health Equity Act was also passed at this
time, however, only two of the twenty bills under this Act went
through, which included the Breast and Cervical Cancer Mortality
Prevention Act and Medicare screening for mammography.32 Still,
heart disease remained a strong concern in the area women's health
and was still not receiving the same focus as it was for men. By
2000 another GAO report was published and mentioned that
women were finally being included in clinical trials at rates
proportional to their general number in the population. 33 Yet it did
not mention the specific clinical trials that were including women.
Along with this report came criticism, and even more concerns
began to develop. Just a year later, in 2001, the GAO found that
the FDA was not effectively monitoring the research data to
determine how sex differences affect a drug's safety and
29 Goldenberg, Marvin M., Politics and Clinical Trials: The Inclusion of
Women, 28 PHARMACY & THERAPuTIcs 791, 793 (Dec. 2003).30 
Id.
31 Id.
32 Keitt, supra note 5, at 257, citing, Women's Health Equity Act of 1990, H.R.
5397, 101 " Cong.; Women's Health Equity Act of 1990, S. 2961, 101" Cong.
3 3 d. at 262.
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effectiveness. 34 This remained a concern because although women
were used in clinical research, there was still a need to analyze the
data by sex to produce sufficient knowledge on this area of
women's health. This is critical in the understanding of how men
and women differ in their responses to drugs.
Although there remain many struggles in medical research
and the participation in clinical trials, there have been vast
improvements as strategies continue to develop. One such strategy
is that of community-based research rather than a focus on
recruitment of subjects. In a community-based model, research
would take place in communities and would involve active
participation by members in the formation of the research project.
35
A goal of this project is that of getting involved in a community
beyond the scope of research. This would show respect for the
community as well as a principle of "do no harm" to the
36communities that would become involved. This idea of
community-based research would most likely help an area with a
high population of minority women, since both involvement and
closeness by researchers may aid them in choosing to participate in
trials with a reassurance of follow-through.
With new ideas and a profound focus on the participation
of women, the 2 1st century represents a promising outlook for this
area of medical research. Not only has the FDA become more
involved, but pharmaceutical companies and their researchers are
also beginning to understand the importance of women in clinical
trials. Medical research is finally beginning to recognize the
importance of distinguishing the differences between both genders
of the human race and the interplay of the pharmaceutical industry.
With every new trial a new piece of research becomes important in
the understanding of the human body for both men and women.
34 Milestones in the Inclusion of Women, at http://www.womens-health.org (last
visited Mar. 30, 2004).
35 Killien, Marcia et al., Involving Minority and Underrepresented Women in
Clinical Trials: The National Centers of Excellence in Women's Health, 9 J.
WOMEN'S HEALTH & GENDER-BASED MED. 1061-1070 at 1067 (2000).
36 Id. at 1066.
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